Jennifer, also known as, “Trie”, is an Associate Director in Medical Affairs for Jazz Pharmaceuticals, leading the Cannabinoid Science Education program. Trie has been working in the cannabinoid science space for nearly 7 years and was instrumental in building the content for CannabinoidClinical.com educational website and leads the Cannabinoid Education Working Group. Trie has presented to learners across the United States including scientific and healthcare providers, advocacy groups, medical societies, state government and policy making members, and beyond the US including the UN Commission on Narcotic Drugs. Prior to her current role, Trie was a Medical Science Liaison at Greenwich Biosciences, US subsidiary of GW Pharmaceuticals, providing scientific support to develop an FDA-approved cannabidiol therapy for the treatment of seizures associated with epilepsy. Trie received her Master of Science in Cellular and Molecular Biology from Saint Cloud State University and her PhD in Comparative and Molecular Biosciences at the University of Minnesota, School of Veterinary Medicine. Before graduate school, she spent several years working in academia performing laboratory research focused on neuroendocrinology.
Perhaps 100 young people may be prescribed opioid pain killers for extracts wisdom teeth or a broken bone and only a handful may feel...
What is the aftermath of the COVID pandemic in terms of damage from drugs? What is the science behind helpful or harmful effects of...
What does the Bible say about Drug, Alcohol, and Addiction? Are there words of ancient wisdom that apply to our modern times? I asked...